Document Detail


Current status and future prospective of immunointervention in multiple sclerosis.
MedLine Citation:
PMID:  16918358     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Multiple sclerosis (MS) is a complex neurological disorder characterized by inflammation and degeneration of the central nervous system, primarily involving the white matter. On the basis of a wide body of evidence in experimental models and in affected patients, several attempts to treat MS using drugs which modulate immune reactions have been performed or are currently ongoing. However, it should be stressed that inflammation does not have only a detrimental effect in MS. In fact, parts of the inflammatory events are crucial for the control and conclusion of the acute phase of damage and it is probable that they actually favor regeneration and recovery. Due to the above, several trials with immunosuppressant drugs failed or were suspended because of unexpected worsening of the course of MS. The knowledge of MS immunopathogenesis is so rapidly evolving that any attempt to review it is in some way frustrating. On the other hand, this evolution is at the basis of the several new treatment options which can be hypothesized for this disease. The current status of immunosuppression in MS and the possible future development of MS treatment will be reviewed, with particular reference to those treatments which have already been tested in clinical trials and which are based on sound evidence of a putative interference with specific events occurring in MS, with the sparing of general immunity.
Authors:
Guido Cavaletti
Related Documents :
21532928 - In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.
14644438 - Cyclophilin sensitivity to sanglifehrin a can be correlated to the same specific trypto...
25184998 - Malaria on the guiana shield: a review of the situation in french guiana.
6395678 - A dual effect of tilorone on multiplication of mycobacterium leprae in mice.
6149298 - In vitro interaction of neuroleptics and tricylic antidepressants with coffee, tea, and...
10780168 - The in vitro secretion of acetylcholinesterase by adult stages of heligmosomoides polyg...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current medicinal chemistry     Volume:  13     ISSN:  0929-8673     ISO Abbreviation:  Curr. Med. Chem.     Publication Date:  2006  
Date Detail:
Created Date:  2006-08-21     Completed Date:  2006-09-11     Revised Date:  2007-02-12    
Medline Journal Info:
Nlm Unique ID:  9440157     Medline TA:  Curr Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  2329-43     Citation Subset:  IM    
Affiliation:
Dipartimento di Neuroscienze e Tecnologie Biomediche, Università di Milano Bicocca, Monza (MI), Italy. guido.cavaletti@unimib.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Azathioprine / therapeutic use
Bone Marrow Transplantation
Cyclophosphamide / therapeutic use
Humans
Immunoglobulins, Intravenous / therapeutic use
Immunosuppressive Agents / therapeutic use
Immunotherapy / methods*,  trends*
Inflammation
Multiple Sclerosis / drug therapy,  immunology*,  therapy*
Chemical
Reg. No./Substance:
0/Immunoglobulins, Intravenous; 0/Immunosuppressive Agents; 446-86-6/Azathioprine; 50-18-0/Cyclophosphamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Inhibitors of cathepsin B.
Next Document:  Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.